Formulation Development
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
Zentalis Pharmaceuticals, Inc. recently announced the US FDA has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation…
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed With Phase 2 Trial for LSALT Peptide
Arch Biopartners Inc. recently announced the University of Calgary’s Conjoint Health Research Ethics Board (CHREB) has approved the Phase 2 trial for LSALT peptide targeting…
Celonic Inaugurates Next-Gen Biologics Development Center & Pilot Plant
The Celonic Group recently opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland. This laboratory expansion will help pharmaceutical companies develop…
Actylis Announces Appointment of Scott Thomson as Chief Executive Officer
Actylis, a leading global manufacturer and sourcing expert of critical materials and performance ingredients for the life sciences and specialty chemicals markets, today announced the…
Zymeworks Announces FDA Clearance of IND Application for Novel 2+1 T-Cell Targeting Bispecific Antibody For Mesothelin-Expressing Cancers
Zymeworks Inc. recently announced the US FDA has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for…
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data
Barinthus Biotherapeutics plc recently announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease. The…
Greenwich LifeSciences Announces $2.5-Million Private Placement
Greenwich LifeSciences, Inc. recently announced it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale…
LIXTE Biotechnology Announces Collaboration on New Colon Cancer Clinical Trial
LIXTE Biotechnology Holdings, Inc. recently announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive…
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for AI-Designed Personalized Cancer Vaccine
Evaxion Biotech A/S recently announced publication of data from its Phase 1 dose escalation study of its lead personalized cancer vaccine candidate, EVX-01, for metastatic…
Grifols’ Biotest Receives FDA Approval for Innovative Immunoglobulin
Grifols recently announced Biotest, a Grifols Group company, has received approval from the US FDA for Yimmugo, an innovative intravenous immunoglobulin (Ig) therapeutic, to treat primary…
Biosplice Announces Collaboration With Novo Nordisk in Diabetes
Biosplice Therapeutics, Inc. recently entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes. This agreement builds upon Biosplice’s innovative…
CERo Therapeutics Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound
CERo Therapeutics Holdings, Inc. recently announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The completion of multiple manufacturing runs is required…
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
Lisata Therapeutics, Inc. recently announced the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial. This investigator-initiated trial,…
WHITEPAPER - Efficient Development of Miniature Drug-Loaded Implants
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at…
Bespak Reaches Key Milestone in the Expansion of its Manufacturing Capacity, with Further Expansion Plans Underway to Meet Global Customer Demand for Climate Friendly Inhalers
Bespak recently announcing progress in its commitment to the production of low global warming potential (GWP) pressurised metered dose inhalers (pMDIs) with the arrival of…
Biora Therapeutics Announces Presentation on the BioJet Systemic Oral Delivery Platform
Biora Therapeutics, Inc. recently announced it will present preclinical data from the BioJet Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery…
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
Tiziana Life Sciences, Ltd. recently announced it has received acceptance of its submission for intranasal foralumab to receive Fast Track Designation approval for the treatment…
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease
Belite Bio, Inc recently announced its lead pipeline, Tinlarebant, has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan (MHLW)…
Enterprise Therapeutics Publishes Preclinical Profile of a Novel Inhaled ENaC Blocker
Enterprise Therapeutics Ltd recently announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis. The paper describes low doses of the…
OBI Pharma Announces Phase 1/2 Study Initiation for a TROP2-Targeted ADC for Cancer Therapy
OBI Pharma recently announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an…
